SpaceX vs. Rocket Lab: Which Space Stock Has More Room to Run?

SpaceX is expected to debut at a roughly $2 trillion valuation, versus Rocket Lab at $85.7 billion, making SpaceX about 22 times larger but cheaper at 107x 2025 sales versus Rocket Lab's 142x. Both companies are still unprofitable, with 2025 net losses of $4.9 billion for SpaceX and $198 million for Rocket Lab, and both are reinvesting heavily in R&D ($9.5 billion and $271 million, respectively). The article argues SpaceX may have the stronger setup because it can fund far more R&D while growing revenue 33.5% year over year.

Analysis

The market is implicitly treating “bigger” as “more upside,” but the more important variable is capital intensity. SpaceX’s scale lets it brute-force iteration with far larger R&D budgets, which can compound into faster product cadence, better reliability, and lower unit costs — the real drivers of long-duration valuation. That creates a structural moat that a smaller, more financially constrained competitor may struggle to close even if its revenue growth is slightly faster today.

The second-order read-through is negative for any pure-play launch hardware ecosystem that depends on frequent capital raises to fund the next platform shift. If SpaceX’s valuation resets smoothly into public markets, it can become the default benchmark for space-sector multiple compression: rivals will be judged not on “growth” alone, but on how much gross profit they can convert into meaningful platform reinvestment. That favors suppliers and software/adjacent names with less execution risk, and it raises the hurdle for standalone launcher equities.

Near term, the biggest catalyst is not the IPO itself but the first few quarters of post-listing disclosures. If unit economics or backlog quality disappoints, the market will likely punish the whole category over days-to-weeks; if SpaceX demonstrates durable free-cash-flow optionality from existing assets, it can drain relative enthusiasm from lower-scale peers over months. The main tail risk to the bearish relative view is a successful Neutron/adjacent program milestone that proves Rocket Lab can graduate from “growth story” to credible platform company before valuation math fully catches up.

The contrarian miss is that Rocket Lab’s cheaper nominal size may actually be a trap: smaller companies often need multiple financing cycles just to preserve growth, which dilutes per-share upside even when the business scales. In that regime, the better trade is not “own the cheaper name,” but own the company that can self-fund iteration fastest and longest.

Key Decisions for Investors

• Short RKLB vs long a basket of profitable aerospace/defense suppliers for 3-6 months; thesis is valuation compression if SpaceX IPO anchors the sector at higher quality and RKLB remains capital dependent. Use a tight stop if RKLB secures a major program win or margin inflection.
• If SpaceX becomes publicly tradable, look for a put spread on RKLB into strength rather than outright shorting; the path dependency is lower and you avoid squeeze risk if retail crowds into the cheaper nominal stock.
• Avoid chasing the IPO on day 1 unless pricing is materially below the implied 100x+ sales framework; upside from the listing is likely in ancillary winners, not the headline name, unless early filings show surprise FCF leverage.
• Prefer suppliers and enabling tech over launch equities over 6-12 months; the best risk/reward is in picks-and-shovels names that benefit from higher sector spending without bearing the binary execution risk of rocket development.
• Set a catalyst watch on the first two post-IPO earnings cycles: if SpaceX shows improving cash conversion while RKLB still burns cash at >100% of gross profit, the relative short becomes more attractive.